Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CSL ( (AU:CSL) ).
CSL has announced the FDA approval of ANDEMBRY®, a groundbreaking treatment for hereditary angioedema (HAE), marking its immediate launch in the United States. This approval enhances CSL’s market positioning, offering the first and only prophylactic treatment targeting factor XIIa for HAE, with significant efficacy demonstrated in clinical trials. The treatment’s approval in multiple regions, including the EU and Japan, underscores its global impact and potential benefits for patients, stakeholders, and the company’s operations.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL is a global biotechnology company based in Melbourne, Australia, specializing in the development and delivery of innovative medicines and therapies. The company focuses on treating rare and serious diseases, with a strong emphasis on immunology and hematology.
YTD Price Performance: -14.49%
Average Trading Volume: 893,127
Technical Sentiment Signal: Sell
Current Market Cap: A$115.7B
See more insights into CSL stock on TipRanks’ Stock Analysis page.